Zacks Investment Research upgraded shares of ChemoCentryx, Inc. (NASDAQ:CCXI) from a hold rating to a buy rating in a report released on Friday morning. Zacks Investment Research currently has $8.25 price objective on the biopharmaceutical company’s stock.
According to Zacks, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. “
CCXI has been the topic of several other reports. Cowen and Company reiterated a hold rating on shares of ChemoCentryx in a research note on Tuesday, August 8th. BidaskClub lowered shares of ChemoCentryx from a buy rating to a hold rating in a research note on Friday, August 18th. Finally, ValuEngine lowered shares of ChemoCentryx from a hold rating to a sell rating in a research note on Saturday, October 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $8.25.
Shares of ChemoCentryx (NASDAQ CCXI) traded up $0.08 on Friday, hitting $7.49. 59,000 shares of the stock were exchanged, compared to its average volume of 141,167. ChemoCentryx has a fifty-two week low of $6.13 and a fifty-two week high of $10.80.
ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.13. sell-side analysts anticipate that ChemoCentryx will post -0.67 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://ledgergazette.com/2017/11/13/chemocentryx-inc-ccxi-raised-to-buy-at-zacks-investment-research.html.
A number of large investors have recently made changes to their positions in CCXI. TIAA CREF Investment Management LLC raised its stake in ChemoCentryx by 37.5% during the 1st quarter. TIAA CREF Investment Management LLC now owns 128,546 shares of the biopharmaceutical company’s stock worth $936,000 after acquiring an additional 35,049 shares in the last quarter. Vanguard Group Inc. raised its stake in ChemoCentryx by 4.1% during the 1st quarter. Vanguard Group Inc. now owns 1,198,730 shares of the biopharmaceutical company’s stock worth $8,727,000 after acquiring an additional 47,475 shares in the last quarter. Geode Capital Management LLC raised its stake in ChemoCentryx by 4.6% during the 1st quarter. Geode Capital Management LLC now owns 196,708 shares of the biopharmaceutical company’s stock worth $1,432,000 after acquiring an additional 8,697 shares in the last quarter. Renaissance Technologies LLC raised its stake in ChemoCentryx by 31.0% during the 1st quarter. Renaissance Technologies LLC now owns 616,581 shares of the biopharmaceutical company’s stock worth $4,489,000 after acquiring an additional 146,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in ChemoCentryx by 35.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 79,299 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 20,955 shares in the last quarter. Hedge funds and other institutional investors own 49.15% of the company’s stock.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.